Related Experiment Video
Updated: Sep 3, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Drug treatment of clinical problems related to cardiac transplantation
Shelley Hankins1, Donna Mancini
1Department of Medicine, Division of Circulatory Physiology, Columbia Presbyterian Hospital Center, New York, New York, USA.
Heart Disease (Hagerstown, Md.)
|July 31, 2002
Abstract:
In recent years, several new immunosuppressive agents have become available for the treatment of cardiac transplant recipients. Use of these agents and their potential side effects are reviewed.
Insights
New immunosuppressive agents offer improved treatment for cardiac transplant recipients. This review covers their use and potential side effects, aiding clinical decision-making.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Cardiac transplantation is a vital treatment for end-stage heart failure.
- Effective immunosuppression is crucial for long-term graft survival.
- Recent advancements have introduced novel immunosuppressive therapies.
Purpose of the Study:
- To review newly available immunosuppressive agents for cardiac transplant recipients.
- To discuss the clinical application and potential adverse effects of these agents.
Main Methods:
- Literature review of recent studies and clinical trials.
- Analysis of pharmacological profiles and side effect data.
- Synthesis of current clinical practice guidelines.
Main Results:
- Several new immunosuppressive agents are now available.
- These agents offer varied mechanisms of action and efficacy.
- Potential side effects range from infections to organ-specific toxicities.
Conclusions:
- New immunosuppressive agents expand treatment options for cardiac transplant patients.
- Careful monitoring for side effects is essential for optimizing patient outcomes.
- Individualized immunosuppressive regimens are key to successful transplantation.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...